ROIV Roivant Sciences Ltd.

XNAS 39.09 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ROIV $39.09 —
Key stats
$39.09
52-Week Range
$19.96 – $42.50
YTD
+78.27%
IV Rank (30D)
63.89
Straddle Price
$5.10
P/C Vol Ratio
1.45
Market Cap
$28.1B
Open
$39.08
Day Range
$38.75 – $39.79
Volume
2,825,343
Prev Close
$38.73
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY0.87
Cost of Equity (CAPM)9.52% (VRP-adj)
WACC9.41%
Volatility Risk Premium+36.7pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-8.6%
Book / Price16.4%
Gross Margin (TTM)91.9%
FCF Margin (TTM)-96.0%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$37.32 (Market Anchor value)
SMA 20 / Bollinger Mid$38.05
Bollinger Width / SMA2018.6% (drives anchor stability)
Net Debt$-1.6B
Market Cap$28B
Peers used for multiples: BTSG, GH, GILD, JNJ, LLY, MRK, RVMD, VRTX
60-Day Conviction
57%
20-Day Fair Value
≈ by Dec 17, 2026
$38.74
α +0.0% rank 29%
conviction
3%
40-Day Fair Value
≈ by Jan 15, 2027
$38.66
α -0.2% rank 29%
conviction
13%
60-Day Fair Value
≈ by Feb 15, 2027
$38.22
α -1.3% rank 29%
conviction
57%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 42.3× · 5 peers
Peer EV/EBITDA n/a 0% median 28.9× · 6 peers
Peer P/B $53.03 14% median 8.3× · 7 peers
Peer P/S $0.54 14% median 8.7× · 8 peers
Market Anchor (SMA50) $37.32 42% stability 57% (BB-width)
Options Expected (B-L 30d) $38.69 29% 16 strikes · skew +0.55
As of 2026-11-18 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$28.1B
Employees
721
List Date
2021-10-01
CIK
0001635088
Last Earnings
Nov 9 before open · +4.6% vs ±13.2% expected
Next Earnings
~Feb 5, 2027 (estimated)
Headquarters
London
Homepage
https://www.roivant.com

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan---29.87%16.08%-11.89%-7.86%-1.41%-6.99%
Feb---12.15%-5.27%13.83%0.37%31.91%5.74%
Mar---22.08%-6.82%-10.45%-0.79%-1.42%-8.31%
Apr---23.76%15.54%4.51%17.97%2.48%3.35%
May--15.32%5.45%-7.58%-5.09%7.76%3.17%
Jun--0.74%7.81%-2.67%0.90%21.66%5.69%
Jul---9.95%22.75%0.18%3.84%-3.21%2.72%
Aug---3.26%-3.02%15.16%5.48%3.96%3.66%
Sep---9.55%0.00%-1.95%22.11%5.94%3.31%
Oct-15.08%52.98%-17.83%1.58%26.92%3.97%8.76%
Nov-15.11%1.13%5.52%8.82%6.17%7.91%*2.41%
Dec13.39%37.76%14.01%-5.21%7.32%--13.45%
Total-18.26%-28.60%58.38%0.08%100.48%106.00%36.35%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $38.23
SMA 50: $37.23
SMA 200: $32.65
Current: $39.11
EMA 12: $38.89
EMA 26: $38.07
MACD: 0.8210 | Signal: -0.0207
BULLISH
ADX (14): 18.26
RANGE
+DI: 28.29
−DI: 22.03

Momentum Oscillators

RSI (14): 55.17
NEUTRAL
Stoch %K: 49.25
Stoch %D: 48.92
Williams %R: -46.86

Volume & Volatility

BB Upper: $41.74
BB Lower: $34.73
NEUTRAL
OBV: 347,429,041
Vol SMA 20: 7,788,421
Vol ROC: -72.52%
ATR: $1.47
True Range: $1.06
HV 20: 46.9%
HV 30: 45.6%
HV 60: 54.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before ROIV’s Nov 9 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 7/10)

Key Drivers and Primary Risks:

  • Strong technical signals, including a bullish MACD crossover and rising RSI
  • Positive news sentiment, driven by developments in the myasthenia gravis market and Priovant's expansion of its brepocitinib development program
  • Above-average volatility, potentially amplifying price movements

Investment Thesis:

ROIV has strong technical momentum, driven by a series of positive news headlines. The stock is trading above its short-term moving averages and showing signs of consolidation. While there are some risks present, such as high volatility and potential market corrections, the overall sentiment remains bullish.

Recent News Sentiment Impact: Positive news sentiment has had a significant impact on ROIV's price movement, driving it higher over the past few weeks.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Uptrend
  • Medium-term (1-3 months): Bullish momentum
  • Long-term (3-12 months): Consolidation with an uptrend bias

Support/Resistance Levels:

  • SMA 20: $34.49
  • SMA 50: $32.98
  • Upper Bollinger Band: $35.81

Momentum Signals:

  • RSI interpretation: Neutral (59.76)
  • MACD signal: Bullish
  • Bollinger Bands position: Squeeze

Volume Analysis: Volume is trading within a moderate range, with no clear trends or patterns.

News & Sentiment Analysis

Recent Headlines Summary:

The past few weeks have seen a string of positive news headlines, including developments in the myasthenia gravis market and Priovant's expansion of its brepocitinib development program. These headlines have driven a strong uptrend in ROIV's price.

Sentiment Assessment: Positive sentiment has dominated, with an overall sentiment score of 0.85 (out of 1).

Catalyst Identification:

  • Upcoming events: Priovant's Phase 2b/3 trial results and the expansion of brepocitinib development program
  • Regulatory changes: FDA approvals for myasthenia gravis treatments

Risk & Volatility Assessment

Beta Interpretation: ROIV has a beta of 1.07, indicating above-average volatility relative to the market.

Volatility Regime: Current volatility is higher than historical levels.

Options Market Signals:

  • IV rank: Low (8.5%)
  • Put/call ratio: Neutral (0.86)

Downside Protection: Support levels include SMA 20 and SMA 50, with potential for further upside if these levels are broken.

Market Context & Positioning

Sector Performance: ROIV is outperforming the broader market sector.

Institutional Activity: Institutional interest is moderate to high, based on volume patterns and options activity.

Correlation Analysis: ROIV has a relatively low correlation with the market (R-squared = 0.32).

Relative Valuation: ROIV is trading within its historical range, with no clear signs of overvaluation or undervaluation.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $34.49
  • Upper Bollinger Band: $35.81

Breakout/Breakdown Levels:

  • SMA 50: $32.98 (potential support level)
  • Lower Bollinger Band: $33.18 (potential resistance level)

Time-Sensitive Catalysts: Priovant's Phase 2b/3 trial results and the expansion of brepocitinib development program.

Risk Management: Stop-loss levels should be set at SMA 20, with position sizing considerations based on the stock's volatility and market conditions.

Generated
Earnings History
16 of 19 under expected move
Avg Expected Move
9.25%
Avg Actual Move
3.67%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2022-02-14 After-Close 4.17% 0.28% 0.07x Within
2022-05-24 After-Close 34.53% 1.02% 0.03x Within
2022-08-15 After-Close 19.06% 2.82% 0.15x Within
2023-02-01 After-Close 6.91% 11.12% 1.61x Exceeded
2023-06-28 After-Close 11.72% 1.69% 0.14x Within
2023-08-14 After-Close 1.20% 6.32% 5.27x Exceeded
2023-11-13 After-Close 6.08% 2.76% 0.45x Within
2024-02-13 After-Close 4.63% 4.81% 1.04x Exceeded
2024-05-30 After-Close 7.46% 0.29% 0.04x Within
2024-08-08 After-Close 9.22% 2.49% 0.27x Within
2024-11-12 After-Close 3.87% 2.66% 0.69x Within
2025-02-10 Pre-Market 6.20% 0.92% 0.15x Within
2025-05-29 Pre-Market 7.77% 6.40% 0.82x Within
2025-08-11 After-Close 3.80% 3.58% 0.94x Within
2025-11-10 Pre-Market 7.76% 2.67% 0.34x Within
2026-02-06 After-Close 8.81% 7.16% 0.81x Within
2026-05-20 After-Close 9.87% 4.72% 0.48x Within
2026-08-06 After-Close 9.54% 3.47% 0.36x Within
2026-11-09 Pre-Market 13.18% 4.60% 0.35x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ROIV Options Activity & IV Rank

ROIV IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 57.0%
7-DTE IV: —
Expected Move: $5.10
7-DTE Move: $2.58
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 2,006
Put Volume: 2,909
P/C Volume: 1.45
BEARISH
Call OI: 64,685
Put OI: 27,055
P/C OI: 0.418
Total OI: 91,740

ATM Options Pricing

ATM Call: $2.55
ATM Put: $2.55
Call %: 6.5%
Put %: 6.5%

Chain Summary

Chain Volume: 4,915
Chain OI: 91,740
Last Updated: 11/19/2026

ROIV Implied Volatility

30-day IV
57.0%
Nov 19
IV rank
64Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much ROIV actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 100th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
100%
vs own history
GEX tilt
+0.86
OI-weighted, today
Vanna tilt
+0.51
δ-sensitivity to IV
Charm tilt
+0.42
δ-decay vs time
Vanna tilt +0.51: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.42: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 36 ATM contracts, 32k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 58.4% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)63.9MediumNov 19

Embed ROIV IV rank

ROIV's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$5.10Nov 19
Beta Analysis

Risk Metrics

Beta: 1.1477
Alpha: 62.01%
Correlation: 0.3289
R-Squared: 10.8%
Stock Volatility: 48.0%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own ROIV
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Viking Global Hedge fund
Andreas Halvorsen
$221.9M
0.63%
#52 of 90-5.7%13F
Citadel Hedge fund
Ken Griffin
$197.3M
0.11%
#194 of 6285+121.6%13F
Point72 Hedge fund
Steve Cohen
$158.3M
0.24%
#96 of 1945+402.1%13F
Rockefeller Capital Management Family office
Rockefeller family
$44.7M
0.07%
#273 of 4858+2145.7%13F
Millennium Management Hedge fund
Izzy Englander
$24.8M
0.02%
#1003 of 3716-12.9%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ROIV Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 714,437,922 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

532 filers590,061,325 shares$21.28B value82.59% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 81,020,390 $2.87B 13.48% 11.34% 2026-06-30
2 BlackRock, Inc. Custodian 61,879,232 $2.26B 10.64% 8.66% 2026-09-30
3 Morgan Stanley Custodian 38,603,606 $1.41B 6.63% 5.40% 2026-09-30
4 Vanguard Capital Management LLC 23,127,563 $845.77M 3.98% 3.24% 2026-09-30
5 QVT Financial LP 23,723,074 $839.56M 3.95% 3.32% 2026-06-30
6 State Street Corp 22,399,587 $819.15M 3.85% 3.14% 2026-09-30
7 FARALLON CAPITAL MANAGEMENT, L.L.C. 21,745,533 $795.23M 3.74% 3.04% 2026-09-30
8 Vanguard Portfolio Management LLC 21,657,255 $792.01M 3.72% 3.03% 2026-09-30
9 Goldman Sachs Group Inc Custodian 18,556,458 $656.71M 3.09% 2.60% 2026-06-30
10 UBS Group AG Custodian 13,928,426 $509.36M 2.39% 1.95% 2026-09-30
11 Geode Capital Management, LLC Custodian 12,521,620 $467.99M 2.20% 1.75% 2026-09-30
12 ADAGE CAPITAL PARTNERS GP, L.L.C. 10,349,328 $366.26M 1.72% 1.45% 2026-06-30
13 Invesco Ltd. Custodian 9,137,172 $334.15M 1.57% 1.28% 2026-09-30
14 JPMorgan Chase & Co Custodian 8,300,820 $304.00M 1.43% 1.16% 2026-09-30
15 PERCEPTIVE ADVISORS LLC 8,085,461 $286.14M 1.34% 1.13% 2026-06-30
16 Patient Square Capital LP 7,710,928 $281.99M 1.33% 1.08% 2026-09-30
17 Assenagon Asset Management S.A. 7,382,971 $270.00M 1.27% 1.03% 2026-09-30
18 Two Seas Capital LP 7,325,356 $267.89M 1.26% 1.03% 2026-09-30
19 Darwin Global Management, Ltd. 6,747,300 $234.33M 1.10% 0.94% 2026-06-30
20 AQR Capital Management, LLC Custodian 6,633,560 $234.03M 1.10% 0.93% 2026-06-30
21 VIKING GLOBAL INVESTORS LP 6,271,467 $221.95M 1.04% 0.88% 2026-06-30
22 Rubric Capital Management LP 6,000,000 $212.34M 1.00% 0.84% 2026-06-30
23 Citadel Advisors LLC Custodian 5,576,261 $197.34M 0.93% 0.78% 2026-06-30
24 Dimensional Fund Advisors LP Custodian 4,956,261 $181.25M 0.85% 0.69% 2026-09-30
25 T. Rowe Price Associates, Inc. 4,816,741 $170.47M 0.80% 0.67% 2026-06-30
12 filers$402.84M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $268.13M 66.56% 2026-09-30
2 Two Seas Capital LP $82.08M 20.37% 2026-09-30
3 Susquehanna International Group, LLP Custodian $18.19M 4.51% 2026-06-30
4 Caption Management, LLC $10.79M 2.68% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $9.33M 2.32% 2026-09-30
6 Citadel Advisors LLC Custodian $4.82M 1.20% 2026-06-30
7 Simplex Trading, LLC Custodian $2.93M 0.73% 2026-09-30
8 TUDOR INVESTMENT CORP ET AL $2.72M 0.67% 2026-06-30
9 JPMorgan Chase & Co Custodian $1.20M 0.30% 2026-09-30
10 Citigroup Inc. Custodian $1.08M 0.27% 2026-09-30
11 IMC-Chicago, LLC Custodian $1.01M 0.25% 2026-09-30
12 Point72 Asset Management, L.P. $555.62K 0.14% 2026-06-30
14 filers$378.07M notional
# Filer Notional Value % of Total Period
1 Wells Fargo & Company Custodian $339.74M 89.86% 2026-06-30
2 Susquehanna International Group, LLP Custodian $14.05M 3.72% 2026-06-30
3 Jane Street Group, LLC Custodian $3.95M 1.04% 2026-09-30
4 GROUP ONE TRADING LLC Custodian $3.91M 1.03% 2026-09-30
5 Simplex Trading, LLC Custodian $3.66M 0.97% 2026-09-30
6 Citadel Advisors LLC Custodian $3.56M 0.94% 2026-06-30
7 IMC-Chicago, LLC Custodian $2.65M 0.70% 2026-09-30
8 PEAK6 LLC $2.29M 0.60% 2026-09-30
9 JPMorgan Chase & Co Custodian $1.20M 0.32% 2026-09-30
10 Citigroup Inc. Custodian $1.08M 0.28% 2026-09-30
11 Caption Management, LLC $1.06M 0.28% 2026-06-30
12 TUDOR INVESTMENT CORP ET AL $647.64K 0.17% 2026-06-30
13 Point72 Asset Management, L.P. $233.57K 0.06% 2026-06-30
14 STEMPOINT CAPITAL LP $40.00K 0.01% 2026-06-30

ROIV Insider Trading (Form 4)

Latest: 2026-11-18
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-18 Keith S Manchester Director Mixed
Sell −1,381,762 · Other −3,036,758
−4,418,520 $38.75 -$53.54M EDGAR
2026-11-18 QVT Financial LP Mixed
Other −3,036,758 · Sell −1,381,762
−4,418,520 $38.75 -$53.54M EDGAR
2026-11-18 Daniel Allen Gold Director Mixed
Sell −1,381,762 · Other −3,036,758
−4,418,520 $38.75 -$53.54M EDGAR
2026-11-12 Eric Venker President & Immunovant CEO Sell (S) −187,943 $40.53 -$7.62M EDGAR
2026-11-12 Frank Torti President and Vant Chair Mixed
Other −1,176,143 · Tax −12,800
−1,188,943 $41.04 -$48.79M EDGAR
2026-11-12 Richard Pulik CFO Mixed
Exer +252,365 · Sell −300,000
−47,635 $24.34 -$11.50M EDGAR
2026-11-12 Mayukh Sukhatme President & CIO Mixed
Other −165,444 · Tax −1,737
−167,181 $41.03 -$6.86M EDGAR
2026-11-12 Matthew Gline CEO Mixed
Tax −1,600 · Other −156,307
−157,907 $41.02 -$6.48M EDGAR
2026-11-05 Eric Venker President & Immunovant CEO Sell (S) −200,000 $36.31 -$7.26M EDGAR
2026-10-30 Eric Venker President & Immunovant CEO Sell (S) −200,000 $36.59 -$7.32M EDGAR
2026-10-27 Ilan Oren Director Award (A) +810 — EDGAR
2026-10-27 James C Momtazee Director Mixed
Tax −77 · Grant +383
+306 $36.49 -$2.8K EDGAR
2026-10-27 Epperly Melissa B, Director Mixed
Grant +513 · Tax −116
+397 $36.49 -$4.2K EDGAR
2026-10-22 Eric Venker President & Immunovant CEO Sell (S) −200,000 $35.11 -$7.02M EDGAR
2026-10-20 Mayukh Sukhatme President & CIO Tax (F) −19,976 $33.53 -$669.8K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ROIV Insider Holdings

15 insiders · @ $39.11
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Vivek Ramaswamy 10%+ Owner 47,011,612 $1.84B -$193.16M 10 2025-12-15
2 Daniel Allen Gold Director 28,270,369 $1.11B -$318.89M 14 2026-11-18
3 Keith S Manchester Director 21,058,011 $823.58M -$237.08M 12 2026-11-18
4 Mayukh Sukhatme President & CIO 20,054,401 $784.33M -$124.75M 18 2026-11-12
5 QVT Financial LP 19,304,554 $755.00M -$278.01M 8 2026-11-18
6 Matthew Gline CEO 16,391,229 $641.06M -$69.51M 33 2026-11-12
7 Frank Torti President and Vant Chair 12,306,950 $481.32M -$82.04M 7 2026-11-12
8 Eric Venker President & Immunovant CEO 811,211 $31.73M -$213.62M 57 2026-11-12
9 Richard Pulik CFO 222,046 $8.68M -$21.60M 47 2026-11-12
10 Rakhi Kumar Chief Accounting Officer 162,306 $6.35M -$6.58M 24 2025-02-24
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ROIV Board & Officers

As of SEC filings through Nov 12, 2026

Directors 8

Officers 6

10% owners 1

Changes in the last 10 years (77)
Dec 19, 2025Mayukh Sukhatme listed as President & CIO (previously Pres&Chief Investment Officer) in SEC filings
Jul 29, 2025Frank Torti became President and Vant Chair
Jul 23, 2025Eric Venker listed as President & Immunovant CEO (previously President & COO) in SEC filings
Feb 24, 2025Rakhi Kumar reported in an SEC filing no longer being Chief Accounting Officer
Feb 19, 2025Jennifer Humes became Chief Accounting Officer
Sep 26, 2024QVT Financial LP no longer listed as a 10% owner in SEC filings
Apr 2, 2024Mayukh Sukhatme first listed as a director in an SEC filing
Oct 2, 2023SoftBank Vision Fund L.P. reported in an SEC filing no longer being a 10% owner
Oct 2, 2023Sb Investment Advisers (uk) Ltd reported in an SEC filing no longer being a 10% owner
Oct 2, 2023SVF Investments (UK) Ltd reported in an SEC filing no longer being a 10% owner
Oct 2, 2023SVF Holdings (UK) LLP reported in an SEC filing no longer being a 10% owner
Oct 2, 2023QVT Financial LP no longer listed as a director in SEC filings
Oct 2, 2023QVT Financial LP first listed as a 10% owner in an SEC filing
Sep 26, 2023Eric Venker listed as President & COO (previously Chief Operating Officer) in SEC filings
Jul 31, 2023The company announced the departure of Hiroshi Nomura from the board in an SEC filing
Jul 27, 2023Eric Venker listed as Chief Operating Officer (previously President & COO) in SEC filings
Jun 26, 2023Viking Long Fund Master Ltd. reported in an SEC filing no longer being a 10% owner
Jun 26, 2023Viking Long Fund GP LLC reported in an SEC filing no longer being a 10% owner
Jun 26, 2023Viking Global Performance LLC reported in an SEC filing no longer being a 10% owner
Jun 26, 2023Viking Global Opportunities Portfolio GP LLC reported in an SEC filing no longer being a 10% owner
Not reported recently (6)
  • Dexxon Holdings Ltd. · Last reported as a 10% owner in an SEC filing dated Nov 14, 2022
  • Dan Oren · Last reported as a 10% owner in an SEC filing dated Nov 14, 2022
  • Dexcel Pharma Technologies Ltd. · Last reported as a 10% owner in an SEC filing dated Nov 14, 2022
  • Benjamin Zimmer · Last reported as President, Roivant Health in an SEC filing dated Oct 1, 2021
  • QVT Financial GP LLC · Last reported as a 10% owner in an SEC filing dated Oct 1, 2021
  • SVF GP (Jersey) Ltd · Last reported as a 10% owner in an SEC filing dated Oct 1, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ROIV Proposed Insider Sales (Form 144)

Latest: 2026-11-13
Last 30d: 9 filings · $106.3M notice value  ·  Last 90d: 15 filings · $127.9M notice value · 7 unique filers · 60% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: FRANK M TORTI (1, $50.7M) · Venker Eric (6, $43.7M) · Pulik Richard (2, $12.5M) · MAYUKH SUKHATME (2, $12.4M) · MATTHEW ADAM GLINE (1, $6.7M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-13 144/A RICHARD PULIK Officer 125,000 $5.15M 2026-11-10 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-13 144/A Pulik Richard Officer 175,000 $7.32M 2026-11-11 Morgan Stanley Smith Barney LLC — EDGAR
2026-11-10 Venker Eric Officer 187,943 $7.62M 2026-11-10 Rockefeller Financial LLC 10b5-1 EDGAR
2026-11-10 144/A FRANK M TORTI Officer 1,234,964 $50.73M 2026-11-10 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-10 144/A MATTHEW ADAM GLINE Officer, Director 164,136 $6.73M 2026-11-10 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-10 144/A MAYUKH SUKHATME Officer, Director 173,725 $7.12M 2026-11-10 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-03 Venker Eric Officer 200,000 $7.26M 2026-11-03 Rockefeller Financial LLC 10b5-1 EDGAR
2026-10-28 Venker Eric Officer 200,000 $7.32M 2026-10-28 Rockefeller Financial LLC 10b5-1 EDGAR
2026-10-20 Venker Eric Officer 200,000 $7.02M 2026-10-20 Rockefeller Financial LLC 10b5-1 EDGAR
2026-09-30 Venker Eric Officer 200,000 $7.32M 2026-09-30 Rockefeller Financial LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-09 Earnings results EDGAR
2026-10-21 Regulation FD disclosure EDGAR
2026-09-18 Shareholder vote results EDGAR
2026-09-08 Regulation FD disclosure EDGAR
2026-08-28 Other events EDGAR
2026-08-27 Regulation FD disclosure EDGAR
2026-08-06 Earnings results EDGAR
2026-05-20 Earnings results EDGAR
2026-04-02 Earnings results · Regulation FD disclosure EDGAR
2026-03-03 Regulation FD disclosure EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-05-20 0001635088-26-000061 EDGAR
2025-05-29 0001140361-25-020715 EDGAR
2024-05-30 0001140361-24-028145 EDGAR
2023-06-28 0001140361-23-031798 EDGAR
2022-06-28 0001193125-22-183362 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-09 0001635088-26-000132 EDGAR
2026-08-06 0001635088-26-000090 EDGAR
2026-02-06 0001635088-26-000011 EDGAR
2025-11-10 0001635088-25-000016 EDGAR
2025-08-11 0001140361-25-030001 EDGAR
2025-02-10 0001140361-25-003661 EDGAR
2024-11-12 0001140361-24-046019 EDGAR
2024-08-09 0001140361-24-036642 EDGAR
2024-02-13 0001140361-24-007260 EDGAR
2023-11-13 0001140361-23-052721 EDGAR
ETF Holders
122 ETFs hold ROIV
25 shown · $3.55B total exposure · 0.36% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IJH iShares Core S&P Mid-Cap ETF iShares (BlackRock) 0.63% $756.1M $120.7B 2026-11-17
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.03% $467.4M — 2026-10-31
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.23% $418.4M — 2026-10-31
4 XMMO Invesco S&P MidCap Momentum ETF Invesco 4.28% $260.7M — 2026-11-17
5 VBK Vanguard Morningstar Small-Cap Growth ETF Vanguard 0.55% $234.2M — 2026-10-31
6 VXF Vanguard Extended Market ETF Vanguard 0.24% $226.8M — 2026-10-31
7 IBB iShares Biotechnology ETF iShares (BlackRock) 1.45% $159.3M $10.9B 2026-11-17
8 MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust SPDR (State Street) 0.63% $157.6M $25.0B 2026-11-17
9 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 1.44% $140.0M $9.7B 2026-11-17
10 SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF SPDR (State Street) 0.63% $115.3M $18.3B 2026-11-17
11 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.15% $85.6M $57.0B 2026-11-17
12 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.09% $78.3M — 2026-11-17
13 IJK iShares S&P Mid-Cap 400 Growth ETF iShares (BlackRock) 0.74% $75.0M $10.1B 2026-11-17
14 VHT Vanguard Health Care ETF Vanguard 0.25% $59.1M — 2026-10-31
15 IJJ iShares S&P Mid-Cap 400 Value ETF iShares (BlackRock) 0.52% $44.2M $8.6B 2026-11-17
16 IWD iShares Russell 1000 Value ETF iShares (BlackRock) 0.05% $43.8M $82.5B 2026-11-17
17 MTUM iShares MSCI USA Momentum Factor ETF iShares (BlackRock) 0.22% $35.0M $16.1B 2026-11-17
18 IVOO Vanguard S&P Mid-Cap 400 ETF Vanguard 0.58% $33.9M — 2026-10-31
19 IWS iShares Russell Mid-Cap Value ETF iShares (BlackRock) 0.19% $28.6M $14.6B 2026-11-17
20 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.03% $27.7M $93.0B 2026-11-17
21 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.06% $25.3M — 2026-11-17
22 FPX First Trust US Equity Opportunities ETF First Trust 1.69% $22.0M $1.3B 2026-11-17
23 MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF SPDR (State Street) 0.74% $20.4M $2.7B 2026-11-17
24 VT Vanguard Total World Stock ETF Vanguard 0.02% $17.1M — 2026-10-31
25 QQQJ Invesco NASDAQ Next Gen 100 ETF Invesco 1.49% $16.7M — 2026-11-17
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.49
TTM Revenue
$41.08M
TTM Net Income
$-344.35M
TTM Op. Cash Flow
$-36.39M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '272026-09-30$35.12M$-191.62M$-0.27$594.42M
Q1 '272026-06-30$1.44M$-189.84M$-0.26$-270.50M
Q4 '262026-03-31$2.52M$302.99M$0.42$-163.82M
Q3 '262025-12-31$2.00M$-265.89M$-0.38$-196.48M
Q2 '262025-09-30$1.57M$-113.52M$-0.17$-185.66M
Q1 '262025-06-30$2.17M$-223.35M$-0.33$-204.38M
Q4 '252025-03-31$7.57M$-206.47M$-0.29$-172.56M
Q3 '252024-12-31$9.02M$169.38M$0.23$-207.25M
Q2 '252024-09-30$4.47M$-230.18M$-0.31$-266.81M
Q1 '252024-06-30$7.99M$95.30M$0.12$-192.83M
Q4 '242024-03-31$9.02M$-151.12M$-0.23$-108.46M
Q3 '242023-12-31$15.56M$5.10B$6.03$-210.45M
Q2 2027 • period ending 2026-09-30 • filed 2026-11-09
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
6.09
P/S
681.19
EV/EBITDA
—
EV/Sales
641.21
ROE
-7.5%
ROA
-6.9%
Div Yield
0.00%
FCF Yield
-0.13%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$27.98B
as of 2026-11-19

ROIV vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.23T 43.9 +45.5% +25.2% 37
JNJ Johnson & Johnson $656.5B 40.4 +7.8% +28.4% 89
MRK Merck & Co., Inc. $339.7B 136.2 +4.9% +24.1% 56
GILD Gilead Sciences Inc $209.6B — +6.5% +37.2% 64
VRTX Vertex Pharmaceuticals Inc $136.0B 33.4 +10.5% +14.7% 67
RVMD Revolution Medicines, Inc. Common Stock $34.6B — — +102.1% 68
ROIV Roivant Sciences Ltd. Common Shares $28.1B — +102.1% +78.3% 64
GH Guardant Health, Inc. Common Stock $19.6B — +41.7% +44.4% 31
BTSG BrightSpring Health Services, Inc. Commo $13.6B 34.8 +26.0% +67.0% 19
Peer median $172.8B 40.4 +10.5% +32.8% 60

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
45.51M
SI % of Float
9.06%
Days to Cover
6.07
Short Vol Ratio
56.6%
Free Float
502.52M
Float %
69.6%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-09-22